AR071645A1 - Farmaco combinado - Google Patents

Farmaco combinado

Info

Publication number
AR071645A1
AR071645A1 ARP090100732A ARP090100732A AR071645A1 AR 071645 A1 AR071645 A1 AR 071645A1 AR P090100732 A ARP090100732 A AR P090100732A AR P090100732 A ARP090100732 A AR P090100732A AR 071645 A1 AR071645 A1 AR 071645A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
pharmaceutical agent
inhibitor
group
atom
Prior art date
Application number
ARP090100732A
Other languages
English (en)
Inventor
Shinji Takagi
Masahiro Yaguchi
Yoshikazu Ohta
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR071645A1 publication Critical patent/AR071645A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicacion 1: Un agente farmaceutico caracterizado porque comprende (1) un inhibidor de HER2 que tiene un esqueleto de pirrolopirimidina o un esqueleto de pirazolopirimidina y (2) no m s de un agente farmaceutico seleccionado de un inhibidor de mTOR, un inhibidor de PI3 quinasa y un inhibidor de cMet en combinacion. Reivindicacion 2: El agente farmaceutico de acuerdo con la reivindicacion 1, caracterizado porque el inhibidor de HER2 que tiene un esqueleto de pirrolopirimidina o un esqueleto de pirazolopirimidina es un compuesto representado por la formula (1) en donde W es C(R1) o N, A es un grupo arilo opcionalmente sustituido o un grupo heteroarilo opcionalmente sustituido, X1 es -NR3-Y1-, -O-, -S-, -SO-, -SO2- o -CHR3- en donde R3 es un  tomo de hidrogeno o un grupo hidrocarbonado alif tico opcionalmente sustituido o R3 est  opcionalmente unido a un  tomo de carbono o un hetero tomo en el grupo arilo o el grupo heteroarilo para A para formar una estructura de anillo opcionalmente sustituida, e Y1 es un enlace simple o un alquileno C1-4 opcionalmente sustituido o un -O-alquileno C1-4 opcionalmente sustituido, R1 es un  tomo de hidrogeno o un grupo opcionalmente sustituido unido a traves de un  tomo de carbono, un  tomo de nitrogeno o un  tomo de ox¡geno y R2 es un  tomo de hidrogeno o un grupo opcionalmente sustituido unido a traves de un  tomo de carbono o un  tomo de azufre, o R1 y R2 o R2 y R3 est n opcionalmente unidos entre s¡ para formar una estructura de anillo opcionalmente sustituida, excepto compuestos representados por las formulas (2) o una de sus sales o uno de sus prof rmacos. Reivindicacion 3: El agente farmaceutico de acuerdo con la reivindicacion 1, caracterizado porque el inhibidor de HER2 que tiene un esqueleto de pirrolopirimidina o un esqueleto de pirazolopirimidina es un compuesto representado por la formula (3) en donde R1a es un  tomo de hidrogeno o un grupo opcionalmente sustituido unido a traves de un  tomo de carbono, un  tomo de nitrogeno o un  tomo de ox¡geno, R2a es un grupo opcionalmente sustituido unido a traves de un  tomo de carbono o un  tomo de azufre, o R1a y R2a o R2a y R3a est n opcionalmente unidos entre s¡ para formar una estructura de anillo opcionalmente sustituida, R3a es un  tomo de hidrogeno o un grupo hidrocarbonado alif tico opcionalmente sustituido o R3a est  opcionalmente unido a un  tomo de carbono del grupo fenilo adyacente para formar una estructura de anillo opcionalmente sustituida, Ba es un anillo benceno opcionalmente sustituido, y Ca es un grupo arilo C6-18 opcionalmente sustituido o una de sus sales o uno de sus prof rmacos. Reivindicacion 4: El agente farmaceutico de acuerdo con la reivindicacion 1, caracterizado porque el inhibidor de HER2 que tiene un esqueleto de pirrolopirimidina o un esqueleto de pirazolopirimidina es N-{2-[4-({3-cloro-4-[3-(trifluorometil)fenoxi]fenil}amino)-5H- pirrolo [3,2-d]pirimidin-5-il]etil}-3-hidroxi-3-metilbutanamida o una de sus sales. Reivindicacion 5: El agente farmaceutico de acuerdo con la reivindicacion 1, caracterizado porque el inhibidor de mTOR es rapamicina. Reivindicacion 6: El agente farmaceutico de acuerdo con la reivindicacion 1, caracterizado porque el inhibidor dePI3 quinasa es PI-103. Reivindicacion 7: El agente farmaceutico de acuerdo con la reivindicacion 1, caracterizado porque el inhibidor de cMet es PF2341066. Reivindicacion 8: El agente farmaceutico de acuerdo con la reivindicacion 1, caracterizado porque es un agente para la prevencion o el tratamiento de c ncer.
ARP090100732A 2008-03-03 2009-03-02 Farmaco combinado AR071645A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008052615 2008-03-03

Publications (1)

Publication Number Publication Date
AR071645A1 true AR071645A1 (es) 2010-07-07

Family

ID=41055970

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100732A AR071645A1 (es) 2008-03-03 2009-03-02 Farmaco combinado

Country Status (8)

Country Link
US (1) US20110003805A1 (es)
EP (1) EP2255830A1 (es)
JP (1) JPWO2009110415A1 (es)
AR (1) AR071645A1 (es)
PE (1) PE20091624A1 (es)
TW (1) TW200942544A (es)
UY (1) UY31684A (es)
WO (1) WO2009110415A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102558185B (zh) * 2010-12-09 2016-02-10 中国科学院上海药物研究所 吡啶并吡咯三嗪化合物、其制备方法和用途
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US7547794B2 (en) 2003-04-03 2009-06-16 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
JP4908210B2 (ja) 2003-07-28 2012-04-04 メルク セローノ ソシエテ アノニム Ｐｉ３キナーゼ阻害剤として使用するための２−イミノ−４−（チオ）オキソ−５−ポリシクロビニルアゾリン類
JP4366683B2 (ja) 2003-07-28 2009-11-18 武原 力 熱サイホン
RU2389731C2 (ru) * 2004-06-02 2010-05-20 Такеда Фармасьютикал Компани Лимитед Конденсированное гетероциклическое соединение
AU2005251769B2 (en) 2004-06-04 2008-10-02 Novartis Ag Cancer treatment method
JP2009526761A (ja) 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
TWI398252B (zh) * 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途

Also Published As

Publication number Publication date
PE20091624A1 (es) 2009-11-19
US20110003805A1 (en) 2011-01-06
JPWO2009110415A1 (ja) 2011-07-14
WO2009110415A1 (ja) 2009-09-11
TW200942544A (en) 2009-10-16
EP2255830A1 (en) 2010-12-01
UY31684A (es) 2009-11-10

Similar Documents

Publication Publication Date Title
AR081387A1 (es) Derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta 2 y como antagonistas muscarinicos m3, composiciones farmaceuticas y uso de los mismos.
CO2017001603A2 (es) Compuestos aminopirimidinilo inhibidores de jak
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PA8680701A1 (es) Derivados de oxindol
AR064416A1 (es) Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
EA200800542A1 (ru) Пиридинаминосульфонилзамещенные бензамиды в качестве ингибиторов цитохрома р450 3а4 (cyp3a4)
DOP2010000191A (es) Derivados bis-(sulfonilamino)
WO2007125321A3 (en) Purine and deazapurine derivatives as pharmaceutical compounds
UY29246A1 (es) Nuevos compuestos
SE0402735D0 (sv) Novel compounds
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
PE20160588A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
CL2008002051A1 (es) Compuestos derivados de isoxazol-4-metoxi, triazol-4-metoxi o pirazol-4-metoxi, con actividad agonista del receptor x de farnesoide (fxr); composicion farmaceutica que los contiene; y el uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento de dislipidemia y enfermedades relacionadas.
ECSP088828A (es) 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r
AR081859A1 (es) Pirimidinas 2,4,6-trisustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de tumores sensibles a la inhibicion de la cinasa atr
UY29607A1 (es) Compuestos quimicos
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
ECSP109937A (es) Pirimidil ciclopentanos como inhibidores de la proteína quinasa akt.
PE20081341A1 (es) Inhibidores de la actividad de la akt
UY29614A1 (es) Compuestos químicos
UY29613A1 (es) Compuestos quimicos vi
CO6362009A2 (es) Derivados de morfolinopurina
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY28861A1 (es) Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias

Legal Events

Date Code Title Description
FB Suspension of granting procedure